NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
Clinical Trials
11 trialsNCT01235962 2020-11-23
PROTECT
Novartis
Phase 3 Completed
NCT00387205 2019-03-06
Study To Assess Long Term Safety Of Pazopanib
Novartis
Phase 1 Completed
NCT00861029 2017-11-14
VEG111485: A QTc Study of Pazopanib
GlaxoSmithKline
Phase 1 Completed
NCT00516672 2017-11-13
Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00722293 2017-11-13
A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00992121 2017-11-13
An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma
GlaxoSmithKline
Phase 1 Completed
NCT01064310 2017-04-17
PISCES
Novartis
Phase 3 Completed
NCT00430781 2015-05-08
Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer
GlaxoSmithKline
Phase 2 Completed
NCT01205230 2012-05-22
VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK
GlaxoSmithKline
Phase 4 Completed
NCT00561795 2012-03-22
Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors
GlaxoSmithKline
Phase 2 Completed